Cargando…

Detection of Subclinical Trastuzumab-Induced Cardiotoxicity in Patients with Breast Cancer

Detalles Bibliográficos
Autor principal:	dos Santos, Marília Harumi Higuchi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Cardiologia 2013
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998165/ https://www.ncbi.nlm.nih.gov/pubmed/23917505 http://dx.doi.org/10.5935/abc.20130143

Ejemplares similares

Trastuzumab Cardiotoxicity in Patients with Breast Cancer
por: Freitas, Aguinaldo Figueiredo, et al.
Publicado: (2014)

Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer
por: Arciniegas Calle, Maria C., et al.
Publicado: (2018)

Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
por: Chang, Wei‐Ting, et al.
Publicado: (2021)

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
por: Marinko, Tanja, et al.
Publicado: (2014)

Coq10 for preventing cardiotoxicity in breast cancer patients treated with trastuzumab
por: Al-Hammadi, Nawal, et al.
Publicado: (2023)

Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis
por: Jawa, Zeeshan, et al.
Publicado: (2016)

Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
por: Méndez-Valdés, Gabriel, et al.
Publicado: (2023)

Trastuzumab-related cardiotoxicity: what do we know in 2020?
por: Liu, Jia, et al.
Publicado: (2020)

Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancer
por: Alıcı, Hayri, et al.
Publicado: (2015)

Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer
por: Sato, Akihiko, et al.
Publicado: (2019)

Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients
por: Sayan, Mutlay, et al.
Publicado: (2019)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

Biomarker panel for early screening of trastuzumab -induced cardiotoxicity among breast cancer patients in west virginia
por: Pillai, Sneha S., et al.
Publicado: (2022)

A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients
por: Matos, Erika, et al.
Publicado: (2016)

Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer
por: Marinko, Tanja, et al.
Publicado: (2018)

Cardiotoxicity assessment in breast cancer patients: is it straining?( )
por: Villarraga, Hector, et al.
Publicado: (2022)

Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay
por: Castillo, Cecilia, et al.
Publicado: (2022)

Early Cardiac Function Monitoring for Detection of Subclinical Doxorubicin Cardiotoxicity in Young Adult Patients with Breast Cancer
por: Chung, Woo-Baek, et al.
Publicado: (2013)

Doxorubicin‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol
por: Nicol, Martin, et al.
Publicado: (2021)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor
por: Hu, Hui-Min, et al.
Publicado: (2018)

Risk of Trastuzumab-Related Cardiotoxicity in Early Breast Cancer Patients: A Prospective Observational Study
por: Xue, Jian, et al.
Publicado: (2014)

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
por: Fabiani, Iacopo, et al.
Publicado: (2020)

NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients
por: Blancas, Isabel, et al.
Publicado: (2020)

Ginsenoside Rg2 Attenuated Trastuzumab-Induced Cardiotoxicity in Rats
por: Liu, Guang, et al.
Publicado: (2022)

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
por: Eaton, Holden, et al.
Publicado: (2023)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
por: de la Brassinne Bonardeaux, Orianne, et al.
Publicado: (2023)

Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials
por: Rygiel, Katarzyna
Publicado: (2016)

Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors
por: Tanaka, Satoru, et al.
Publicado: (2017)

High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy
por: Katsurada, Kenichi, et al.
Publicado: (2014)

Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
por: Minichillo, Santino, et al.
Publicado: (2017)

Whole exome sequencing to identify genetic markers for trastuzumab‐induced cardiotoxicity
por: Udagawa, Chihiro, et al.
Publicado: (2018)

Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
por: Zhou, Shijie, et al.
Publicado: (2023)

Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients
por: Zhou, Xi, et al.
Publicado: (2023)

Risk Factors Associated with Trastuzumab-induced Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
por: Abdel-Razaq, Wesam, et al.
Publicado: (2019)

Regional myocardial edema detected by T2 mapping is a feature of cardiotoxicity in breast cancer patients receiving sequential therapy with anthracyclines and trastuzumab
por: Thavendiranathan, Paaladinesh, et al.
Publicado: (2014)

Prediction of doxorubicin cardiotoxicity by early detection of subclinical right ventricular dysfunction
por: Planek, Maria Isabel Camara, et al.
Publicado: (2020)

Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters
por: Díaz‐Antón, Belén, et al.
Publicado: (2022)

Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer
por: Vazdar, Ljubica, et al.
Publicado: (2021)

The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab
por: Huszno, Joanna, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_eeg67rdv87mbphb2m0d5u8rleh